Skip to main content
EP

Epikast

New York, United States
Last funding
$2.2M
Series BJan 2026

Epikast provides technology-enabled commercial and clinical services for the biopharmaceutical industry.

Backed byEcoR1 CapitalKos Biotechnology Partners

About Epikast

How much funding has Epikast raised?

Epikast has raised $2.2M in total funding. The most recent round was Series B. The last funding was announced in January 2026.

Who are Epikast's investors?

Epikast's investors include EcoR1 Capital, Kos Biotechnology Partners.

Where is Epikast headquartered?

Epikast is headquartered in New York, United States.

What does Epikast do?

Epikast provides technology-enabled commercial and clinical services for the biopharmaceutical industry.

What stage is Epikast at?

Epikast is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Epikast — Funding & Investors." VCBacked, January 30, 2026, https://www.vcbacked.co/company/epikast. Accessed November 21, 2026.
APA
VCBacked. (2026). Epikast — Funding & Investors. Retrieved November 21, 2026, from https://www.vcbacked.co/company/epikast
Wikipedia (cite web)
{{cite web |title=Epikast — Funding & Investors |url=https://www.vcbacked.co/company/epikast |website=VCBacked |access-date=November 21, 2026}}

Profile data sourced and verified per the VCbacked methodology · Last funding round dated

Work at Epikast? Request a listing update

Founder contacts
m***@epikast.com
linkedin.com/in/●●●●●●
Emails, phones & LinkedIn · 41,000+ verified contacts
Get instant access →